2020’s Top Hemp Stories

by | Dec 23, 2020

Hemp was on an upward trajectory in terms of market predictions, shifting federal policies, and planted acreage. The COVID-19 pandemic meant that the hemp sector, like many other sectors, took a different journey than what many had predicted. 

Hemp, and hemp-related products like CBD, floundered in 2020 for the first time in the 21st century. The biggest stories about hemp weren't what we all expected. Instead of significant legislative changes, record sales, and insatiable consumer demand, the hemp industry took a nosedive.  

COVID-19 and the Hemp Industry 

Heading into 2020, the CBD sector was entering into an expected period of mergers and acquisitions (M&A), as larger, multinational ones gobbled up smaller players. Viridian Capital Partners told the National Law Review, “There were 94 hemp and cannabis M&A deals in the first quarter of 2019, and there were 19 such deals in the first quarter of 2020, representing approximately 80% fewer.” Based on this assessment and others, the National Law Review estimated a 75 percent downturn in M&A throughout the rest of the year. 

Layered on top of the decline in M&A activity was a general downturn in capital investment. Comparing the number and size of capital raises between 2019 and 2020, we've witnessed more than a 50 percent decrease.  

Down at the hemp cultivator level, an April 2020 article published in Forbes stated that “the coronavirus has intensified the impact of the CBD price crash.” In 2014, processed CBD oil would reach upwards of $70,000 a kilogram, but in 2020 the bottom had fallen out completely. Today, the same kilo brings in as little as $750. 

Like many other affected industries, the hemp industry will likely bounce back to some extent as the world climbs out of the pandemic. But will the consumer demand for everything CBD do the same? 

Green Rush Led to Green Glut 

Twenty-twenty also saw the green rush of farmers falling over themselves to plant acres of hemp finally reach a tipping point. According to Politico, in 2018 (notably before the passage of the 2018 Farm Bill), there were only 78,000 acres of hemp planted. In 2019, there were 511,442 total licensed acres of hemp, and in 2020, 465,787 acres.  

The decline of licensed acres from 2019 to 2020 may be thanks to the CBD and hemp market glut. Even late into 2020, many farmers still reported having 2019 stock to sell. Cultivators who were hoping to turn a profit quickly or get into the industry before their peers are now floundering. The market is still notably unstable, especially compounded with the effects of the COVID-19 pandemic. 

Michigan Farm News interviewed agronomist Christie Apple, who described the current challenges facing hemp farmers. As she explained, because farmers failed to see a return on substantial investments, they are reconsidering hemp. Apple said, “I think a lot of the farmers are having to look at it: Do I keep investing in something that is a fairly unstable market currently? There are a lot of questions, and I think people wanted to try and make that quick buck — and they weren't able to do it.” 

Hemp Regulation, No Decisive Updates But Subtle Shifts 

The hemp market hesitancy is also thanks to several major regulators' failure to make any substantial policy decisions. Two years after the legalization of hemp cultivation by the passage of the 2018 Farm Bill, the Food and Drug Administration is still pondering CBD policy.  

The Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2020 (H.R.8179) is still fumbling through Congress. The FDA has submitted FDA/HHS Technical Comments on H.R. 8179, which are notably counter to the interests of many within the hemp and CBD sectors. The bill's language is open, but the FDA has suggested many restrictions. According to the FDA, the hundreds of other compounds in hemp are unstudied and therefore unsafe.  

As per the FDA's comments, “We are concerned about this lack of safety data, and we are also concerned that by including these other hemp-derived compounds in the bill language, it could disincentivize potential drug development of these compounds and instead encourage the use of these compounds in dietary supplements.” 

At the time of writing, there are no clear predictions for the fate of H.R.8179, nor an estimated date for new CBD- and hemp-derivative regulations from the FDA. Until then, the hemp sector will remain a risky market for investment. 

2020 Fell Flat, But Hope for 2021 

As the glut washes out and cultivators adjust, 2021 may offer a more balanced equilibrium between what's grown and what the market can handle. There is also an indication that growers are seeking alternatives to the CBD oil market and instead are focused on hemp fiber's potential. 

Many are hopeful that the hemp industry will bounce back to some extent in the next 12 months as the world recovers from the many pandemic-related challenges. New guidance from federal regulators and the FDA, which failed to appear in 2020, could also help reinvigorate the market.  

Upcoming Events